Noteworthy - Pharmaceutical Executive



Pharm Exec's Pharma 50 2014

June 9, 2014

For those companies in this year's Pharm Exec Top 50, meeting the accelerating market demand for specialty products has become an acute strategic imperative.

India: Too Big to Overlook

June 2, 2014

India must still be included in the list of promising potential markets for global pharma manufacturers, writes Jill E. Sackman and Michael Kuchenreuther.

Oncology Biomarker Testing: Why the UK Delay?

May 29, 2014

Amy Butcher investigates why the UK is lagging significantly behind Europe in the uptake of oncology biomarker testing — and looks at what the delays mean for pharma.

Reimbursement Limits Threaten Drug Access

May 22, 2014

Despite provisions in the Affordable Care Act that require qualified health plans to cover 'basic' benefits, access to prescription drugs may be limited by high out-of-pocket costs and tight pharmacy management strategies.

Rebuilding European Pharma's Competitive Agenda

May 19, 2014

Because of the tougher conditions they face and shifts in ownership and corporate strategy, EFPIA and EGA have started to work together much more closely.

Gravity Shift: What MNCs Can Learn from Generics

May 15, 2014

MNCs can learn a lot from generic companies in their strategic approaches to emerging markets.

Oncology: Still an Attractive Market?

May 13, 2014

In light of the risks and challenges inherent in the development of oncologics, some pharmacos are questioning whether it remains an attractive therapeutic area in which to invest its resources.

Africa: The Lost Continent No More

May 6, 2014

Driven by a rising GDP and calmer political and financial waters over the past decade, Africa's nascent healthcare sector is poised for a fresh surge in growth.

Brands of Yesteryear: Where Are They Now?

May 6, 2014

We check back with previous Pharm Exec Brand of the Year winners to see how things are going.


Click here